Back to Cell Types

NOMO-1Homo sapiens (Human)Cancer cell line

Also known as: NOMO1, Nomo-1

🤖 AI SummaryBased on 9 publications

Quick Overview

NOMO-1 is a human monocytic leukemia cell line derived from a patient with acute monocytic leukemia (M5a).

Detailed Summary

NOMO-1 is a human monocytic leukemia cell line established from a female patient with acute monocytic leukemia (M5a). This cell line exhibits characteristics of promonocytic cells and can be differentiated into macrophage-like cells upon treatment with 12-O-tetradecanoyl phorbol-13-acetate (TPA). NOMO-1 has been used to study the coagulation and fibrinolysis systems, as well as the expression of tissue factor, plasminogen activator (PA), and plasminogen activator inhibitor (PAI). Research has shown that NOMO-1 cells can be induced to express fibronectin and interleukin-1 (IL-1) α and β upon TPA treatment. Additionally, NOMO-1 has been utilized in studies related to the FLT3 signaling pathway and its role in leukemia, although specific details about these studies are not provided in the available data. The cell line is also noted for its potential in studying the molecular mechanisms of leukemia and the effects of various treatments on cell proliferation and differentiation.

Research Applications

Study of coagulation and fibrinolysis systemsInvestigation of tissue factor, plasminogen activator, and plasminogen activator inhibitor expressionAnalysis of cell differentiation and proliferationResearch on FLT3 signaling pathway in leukemia

Key Characteristics

Promonocytic characteristicsDifferentiation into macrophage-like cells upon TPA treatmentExpression of fibronectin and interleukin-1 upon TPA treatmentPotential for studying leukemia molecular mechanisms

Generated on 6/17/2025

Basic Information

Database ID	CVCL_1609
Species	Homo sapiens (Human)
Tissue Source	Bone marrow[UBERON:UBERON_0002371]

Donor Information

Age	31
Age Category	Adult
Sex	Female

Disease Information

Disease	Acute monoblastic/monocytic leukemia
Lineage	Myeloid
Subtype	Acute Monoblastic/Monocytic Leukemia
OncoTree Code	AMOL

DepMap Information

Source Type	HSRRB
Source ID	ACH-000168_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Cys242Alafs*5 (c.723delC) (p.S241fs)	Homozygous	-	Unknown, Unknown
MutationSimple	KRAS	p.Gly13Asp (c.38G>A)	Heterozygous	Somatic	from parent cell line MDA-MB-231
MutationSimple	EP300	c.730-10T>C	Heterozygous	-	from parent cell line NOMO-1
Gene fusion	KMT2A	KMT2A-MLLT3, MLL-MLLT3, MLL-AF9	-	-	PubMed=31701557

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X

CSF1PO

11,12

D13S317

8,10

D16S539

9,11

D18S51

17,21.2

D19S433

13,14

D21S11

29,32.2

D2S1338

17,23

D3S1358

15,17

D5S818

11,13

D7S820

8,10

D8S1179

13,14

FGA

21,22

Penta D

9,12

Penta E

15,17

TH01

6,9

TPOX

8,12

vWA

17,18

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Screening human cell lines for viral infections applying RNA-Seq data analysis.

Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.

PLoS ONE 14:E0210404-E0210404(2019).

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

Yang H.H., Koeffler H.P.

BMC Cancer 18:940.1-940.13(2018).

Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene.

Pigazzi M., Martelli A.M., Basso G., Locatelli F., Pession A.

J. Hematol. Oncol. 10:26.1-26.5(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Survey of activated FLT3 signaling in leukemia.";

Druker B.J., Heinrich M.C., Rush J., Polakiewicz R.D.

PLoS ONE 6:E19169-E19169(2011).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Malignant hematopoietic cell lines: in vitro models for the study of MLL gene alterations.

Drexler H.G., Quentmeier H., MacLeod R.A.F.

Leukemia 18:227-232(2004).

Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia.

Aizawa Y., Ueda R., Seto M.

Jpn. J. Cancer Res. 89:712-718(1998).

Up-regulation of transferrin receptor gene expression by granulocyte colony-stimulating factor in human myeloid leukemia cells.

Morishima Y., Saito H.

Cancer Res. 50:7955-7961(1990).

Enhanced expression of DNA topoisomerase II by recombinant human granulocyte colony-stimulating factor in human leukemia cells.

Morishima Y., Andoh T., Saito H.

Cancer Res. 50:7198-7202(1990).

Coagulation and fibrinolysis system of a human monocytic leukemia cell line, NOMO-1.

Ogura M., Hamaguchi M.

Nihon Monaikei Gakkai Kaishi 28:19-26(1988).

The leukemia-lymphoma cell line factsbook.";

Drexler H.G.

(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).